Lisata Therapeutics appoints Jeffrey Farrow to board of directors
LSTA•Lisata Therapeutics appointed Jeffrey Farrow to its board effective October 13, 2026, expanding it from seven members to eight. Farrow will serve on the Audit Committee.
1. Board appointment
Lisata Therapeutics appointed Jeffrey Farrow to a newly created Class III board seat, effective October 13, 2026. The appointment expands the board from seven members to eight, and Farrow will serve on the Audit Committee.
2. Farrow’s background
Farrow was chief financial officer of Global Blood Therapeutics from 2016 to 2022, through its acquisition by Pfizer.
